Price
$586.67+4.61%Social Signal Score
Analyst Ratings
23 analystsRevenue
$1.21B+174.10%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Erickson
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 11,000
- Beta
- 1.54
- Country
- US
- Piotroski score
- 9 / 9 (Strong)
- Altman Z-score
- 23.26
Financials
Revenue
$1.21B+174.1%Net Income
$317.14M+505.6%EBITDA
$447.35M+325.5%Free Cash Flow
$420.79M+393.4%EPS (diluted)
$4.01+591.4%Shares Outstanding (diluted)
79.05M-12.7%Operating Expenses
$361.95MCash & Debt
$197.54MReturn of Capital
$112.17MRevenue by Segment (annual)
$4.30BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.30B | $1.06B | $13.17 |
| 2024 | $3.90B | $887.87M | $10.77 |
| 2023 | $3.66B | $845.04M | $10.17 |
| 2022 | $3.37B | $679.09M | $8.12 |
| 2021 | $3.22B | $744.85M | $8.74 |
| 2020 | $2.71B | $581.78M | $6.82 |
| 2019 | $2.41B | $427.72M | $4.97 |
| 2018 | $2.21B | $377.03M | $4.34 |
| 2017 | $1.97B | $263.14M | $3.00 |
| 2016 | $1.78B | $222.04M | $2.47 |
| 2015 | $1.60B | $192.08M | $2.07 |
| 2014 | $1.49B | $181.91M | $1.82 |
| 2013 | $1.38B | $187.80M | $1.77 |
| 2012 | $1.29B | $178.27M | $1.62 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from IDXX's reported EPS growth of 17.5% a year over 13 years.
- EPS in 5 years
- $29.63
- Implied price
- $1,511
- Return from $698.47
- 16.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $751.18 — today's price is already 7.0% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 35 | 43 | 51 | 59 | 67 |
|---|---|---|---|---|---|
| 7.5% | -1.0% | 3.2% | 6.8% | 9.9% | 12.7% |
| 12.5% | 3.6% | 8.0% | 11.7% | 15.0% | 18.0% |
| 17.5% | 8.2% | 12.8% | 16.7% | 20.1% | 23.2% |
| 22.5% | 12.8% | 17.6% | 21.7% | 25.2% | 28.5% |
| 27.5% | 17.4% | 22.4% | 26.6% | 30.4% | 33.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+0.00%Social Signal Score
Mentions (53)
- Newsdefenseworld.net·1d ago·Positive
Water Stocks Worth Watching – November 19th Coca-Cola, Waters, Ecolab, Pentair, Xylem, American Water Works, and IDEXX Laboratories are the seven Water stocks to watch today, according to MarketBeat's stock screener tool. Water stocks are shares in publicly traded companies involved in supplying, treating, or managing water, such as water utilities and firms that make pipes, pumps, or filtration systems. They give
View source ↗ - News (Marketaux)seekingalpha.com·15d ago·Negative
What Moved Markets This Week IDEXX Laboratories (ID[+300 characters]
View source ↗ - Newsdefenseworld.net·15d ago·Negative
IDEXX Laboratories (NASDAQ:IDXX) Stock: Insider Michael Lane Sells 3,979 Shares IDEXX Laboratories, Inc. (NASDAQ: IDXX - Get Free Report) EVP Michael Lane sold 3,979 shares of the business's stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $688.64, for a total transaction of $2,740,098.56. Following the sale, the executive vice president directly owned 4,076 shares of the company's
View source ↗ - Newszacks.com·16d ago·Positive
3 Reasons Growth Investors Will Love Idexx (IDXX) Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
View source ↗ - News (RSS)seekingalpha·18d ago·Positive
IDEXX Laboratories: Q3 Results Confirm They Are Best-In-Class
View source ↗ - Newsseekingalpha.com·18d ago·Negative
…dance to 10.1%-10.8%. VetLab consumables and CAG department revenues grew 16.1% and 11.3% respectively in the first nine months, underscoring core business strength. IDXX maintains pricing power, consistently passing on price increases and offsetting inflation, as evidenced by improved gross and operating margins.
View source ↗ - Newsseekingalpha.com·18d ago·Neutral
…ories delivered strong Q3 results, beating expectations with 9.86% organic revenue growth and raising full-year revenue and EPS guidance. I maintain my buy rating on IDXX, citing its best-in-class diagnostics, high recurring revenue, and robust innovation pipeline supporting premium valuation. CoVet acquisition adds high-margin, AI-driven workflow software, enhancing stickiness and cross-selling, with a calculated purchase price near $223 million and double-digit growth potential.
View source ↗ - Newszacks.com·19d ago·Positive
Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
View source ↗ - News (RSS)thestreet·20d ago·Positive
IDEXX stock soars 21.9% after earnings beat and higher outlook The veterinary diagnostics company saw sales and profit grow more than Wall Street expected.
View source ↗ - News (RSS)thestreet·20d ago·Positive
Non-AI stock surges 20% after earnings beat and raised outlook IDEXX Laboratories raised its full-year earnings and revenue forecasts after stronger demand for its veterinary diagnostic products.
View source ↗ - News (Marketaux)seekingalpha.com·20d ago·Positive
IDEXX Laboratories, Inc. (IDXX) Q3 2026 Earnings Call Transcript Presentation Operator Good morning, an[+152 characters]
View source ↗ - News247wallst.com·20d ago·Neutral
IDEXX Soars 20.2% on Earnings Beat: What It Means for Your S&P 500 Index Fund Retirement savers who never chose IDEXX Laboratories (NASDAQ:IDXX | IDXX Price Prediction) got a lift from it anyway on Monday. The veterinary diagnostics company was up 20.2% in the regular session as of 1:54 PM ET, trading at $662.
View source ↗ - News (RSS)seekingalpha·20d ago·Neutral
IDEXX Laboratories, Inc. 2026 Q3 - Results - Earnings Call Presentation
View source ↗ - News (Marketaux)seekingalpha.com·20d ago·Neutral
IDEXX Laboratories, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:IDXX) 2026-11-02 IDEXX Laboratories, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:IDXX) 2026-11-02
View source ↗ - News (RSS)zerohedge·20d ago·Neutral
…) gains 3% after securing a contract from US Immigration and Customs Enforcement to provide support services at the 2,329-bed Big Spring Complex in Texas.Idexx Labs (IDXX) rises 6% after the animal health firm boosted its revenue guidance for the full year, following results for the third quarter that beat the average analyst estimate.Inovio Pharmaceuticals (INO) rallies 50% after the biotech got accelerated FDA approval for Voceryq, an immunotherapy to treat adults with recurrent respiratory pa…
View source ↗ - Newsreuters.com·20d ago·Negative
IDEXX raises forecast, betting diagnostics can offset weak vet visits IDEXX raises forecast, betting diagnostics can offset weak vet visits
View source ↗ - Newsfool.com·20d ago·Neutral
IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction IDEXX grew third-quarter revenue 10% to about $1.21 billion, led by an 11% gain in recurring diagnostics sales to vets. The higher 2026 profit forecast doesn't come from testing demand.
View source ↗ - Newsmarketbeat.com·20d ago·Neutral
IDEXX Laboratories Q3 Earnings Call Highlights IDEXX Laboratories NASDAQ: IDXX reported third-quarter 2026 results marked by organic revenue growth, higher diagnostic utilization and expanded placement of its premium instruments, while raising its full-year revenue and earnings outlook.
View source ↗ - Newszacks.com·20d ago·Neutral
Idexx (IDXX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newszacks.com·20d ago·Positive
IDXX Q3 Earnings & Revenues Surpass Estimates, Stock Up in Pre-Market IDEXX Laboratories beats Q3 2026 earnings and revenue estimates as diagnostic demand boosts growth and margins expand, prompting higher 2026 revenue and earnings guidance.
View source ↗ - Newszacks.com·20d ago·Positive
Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates Idexx Laboratories (IDXX) came out with quarterly earnings of $3.98 per share, beating the Zacks Consensus Estimate of $3.71 per share. This compares to earnings of $3.4 per share a year ago.
View source ↗ - Newsbusinesswire.com·20d ago·Neutral
IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced third quarter results. Third Quarter Results The Company reports revenues of $1,214 million for the third quarter of 2026, an increase of 10% as reported and organic, driven by Companion Animal Group ("CAG") growth of 10% as reported and organic. Third quarter earnings per diluted share (“EPS”) were $4.01, an …
View source ↗ - Newszacks.com·25d ago·Neutral
Gear Up for Idexx (IDXX) Q3 Earnings: Wall Street Estimates for Key Metrics Get a deeper insight into the potential performance of Idexx (IDXX) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
View source ↗ - Newszacks.com·30d ago·Positive
Here's How IDEXX Laboratories Is Placed Ahead of Q3 Earnings IDXX heads into Q3 earnings with expected revenue and EPS growth, fueled by CAG Diagnostics momentum, higher testing volumes and software gains.
View source ↗ - Newszacks.com·33d ago·Neutral
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report? Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newszacks.com·33d ago·Positive
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
View source ↗ - Newszacks.com·34d ago·Positive
Idexx (IDXX) Moves to Buy: Rationale Behind the Upgrade Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - 4chan /biz/biz·37d ago·Neutral
>>62787964 IDXX another s*** company only up 28% before dropping 15%, which is only 10% over all
View source ↗ - 4chan /biz/biz·37d ago·Neutral
…787858 Nah, I set the criteria for the AI to look for, not the AI Here they are ranked in order: Broadcom (AVGO) Mastercard (MA) MSCI (MSCI) IDEXX Laboratories (IDXX) Visa (V) Moody’s (MCO) Verisk Analytics (VRSK) Fair Isaac (FICO) Taiwan Semiconductor Manufacturing (TSM) Motorola Solutions (MSI) Gaztransport & Technigaz (GTT) Sectra (SECT-B.ST) Intuitive Surgical (ISRG) Rational (RAA.DE) Intuit (INTU) TransDigm Group (TDG) S&P Global (SPGI) Cadence Design Systems (CDNS) NAPC…
View source ↗ - 4chan /biz/biz·51d ago·Neutral
btw if you don't like IDXX replace it with FICO
View source ↗ - 4chan /biz/biz·51d ago·Neutral
…pite that, you can't even imagine all the research that I've done. Here you go. 10 ticker portfolio: >BRK.B 12.5% >JNJ 7.5% >AVGO 15% >CDNS 12.5 >IDCC 12.5 >MA 10% >IDXX 10% >VRSK 7.5% >BMI 7.5% >USLM 5% If you want a more aggressive 6 ticker portfolio. Higher risk for potentially higher reward: >BRK.B 20% >AVGO 25% >IDCC 15% >IDXX 15% >MA 12.5% >BMI 12.5%
View source ↗ - Newsbusinesswire.com·52d ago·Neutral
IDEXX Laboratories to Release 2026 Third Quarter Financial Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, a…
View source ↗ - Newszacks.com·60d ago·Neutral
Should You Continue to Hold IDXX Stock in Your Portfolio? IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.
View source ↗ - Newsmarketbeat.com·63d ago·Positive
IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets IDEXX Laboratories NASDAQ: IDXX executives highlighted the company's diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure on veterinary office visits.
View source ↗ - News (RSS)yahoo·64d ago·Negative
IDEXX (IDXX) Bets an AI Scribe Can Sell More Pet Diagnostics
View source ↗ - Newszacks.com·66d ago·Positive
IDEXX Stock Gains Following the Acquisition of CoVet IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.
View source ↗ - Newsbusinesswire.com·66d ago·Neutral
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.
View source ↗ - News (RSS)investing·67d ago·Neutral
IDEXX acquires AI veterinary workflow software firm CoVet
View source ↗ - News (Marketaux)gurufocus.com·69d ago·Positive
IDEXX Laboratories, Inc. at Morgan Stanley Global Healthcare Conference Transcript We're happy to have IDEXX L[+302 characters]
View source ↗ - Newsseekingalpha.com·69d ago·Positive
IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)fool·73d ago·Negative
Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of Stock Kingsley exercised options at $114.17 per share before immediately selling at $532.08, capturing a significant gain. His direct stake remains at 9,568 shares worth $5.12 million.
View source ↗ - Newszacks.com·83d ago·Positive
Idexx Laboratories (IDXX) is a Top-Ranked Growth Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·90d ago·Positive
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newszacks.com·93d ago·Neutral
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now? IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.
View source ↗ - Newszacks.com·94d ago·Neutral
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.
View source ↗ - Newszacks.com·95d ago·Positive
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation? IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.
View source ↗ - News (RSS)seekingalpha·96d ago·Positive
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
View source ↗ - Newsseekingalpha.com·96d ago·Positive
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript
View source ↗ - News (RSS)seekingalpha·96d ago·Neutral
IDEXX Labs Executing, But Valuation Continues To Weigh On That Execution
View source ↗ - News (RSS)seekingalpha·100d ago·Neutral
IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day - Slideshow
View source ↗ - Newsmarketbeat.com·100d ago·Neutral
IDEXX Laboratories Targets $45B Pet Diagnostics Opportunity With AI, Cancer Tests IDEXX Laboratories NASDAQ: IDXX outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to increase testing utilization in veterinary practices.
View source ↗ - Newszacks.com·102d ago·Positive
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newsseekingalpha.com·106d ago·Positive
IDEXX Laboratories: Worth The Premium IDEXX Laboratories remains a buy, supported by a durable moat, strong recurring revenue, and a long-term international growth runway. Recent Q2 2026 results showed 9% organic revenue growth, EPS guidance raised to $14.69–14.94, and robust expansion of diagnostic offerings. Installed base growth for core machines is moderating in the US but remains early-stage internationally, underpinning multi-decade expansion potential.
View source ↗
Earnings
Mon, Feb 1(in 2 months)
Consensus estimate $3.30 per share
Typical surprise +6.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$3.96 vs $3.73beat
- Tue, Aug 4$4.27 vs $3.94beat
- Tue, May 5$3.47 vs $3.41beat
- Mon, Feb 2$3.08 vs $2.93beat
- Mon, Nov 3$3.40 vs $3.14beat
- Mon, Aug 4$3.63 vs $3.28beat
Estimates and results for IDXX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IDXX officers and directors.
- Bought
- —
- Sold
- $46.8m
0 trades
37 trades
- Underberg Sharon E.sold
- Underberg Sharon E.sold
- Underberg Sharon E.sold
- Mazelsky Jonathan Jaysold
- Mazelsky Jonathan Jaysold
- Mazelsky Jonathan Jaysold
- Mazelsky Jonathan Jaysold
- Mazelsky Jonathan Jaysold
63 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (33d later)Buy$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (28d later)Sell$15,001 - $50,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (14d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (35d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$15,001 - $50,000
- April McClain Delaneyhouse · MD06 · disclosed Feb 3, 2026 (21d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Jan 6, 2026 (35d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Nov 5, 2025 (7d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Nov 5, 2025 (20d later)Sell$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Oct 8, 2025 (34d later)Buy$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Oct 8, 2025 (34d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (28d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Sep 3, 2025 (27d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Sep 3, 2025 (33d later)Sell$1,001 - $15,000
- April McClain Delaneyhouse · MD06 · disclosed Aug 6, 2025 (28d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$100,001 - $250,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 10, 2025 (26d later)Buy$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed May 9, 2025 (32d later)Buy$50,001 - $100,000
- April McClain Delaneyhouse · MD06 · disclosed May 2, 2025 (23d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
